Physician profile
Bert Edward Williams
NPI 1497813208
$2,673.49
in general payments reported to CMS, 2019-2025
24 companies · $1,119 in 2025
The $1,119 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $82.53 · 2020: $261 · 2021: $453 · 2022: $142 · 2023: $337 · 2024: $280 · 2025: $1,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $870 · Travel and Lodging: $865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.33 |
| Travel and Lodging | $865.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $902.79 | 2025 | Axonics |
| Astellas Pharma US INC | $305.74 | 2020-2023 | Myrbetriq |
| Urogen Pharma, INC. | $280.83 | 2020-2025 | Jelmyto |
| Axonics, INC. | $234.62 | 2023-2024 | Axonics |
| Novo Nordisk INC | $112.57 | 2025 | Wegovy |
| Teleflex LLC | $102.62 | 2022 | |
| Sumitomo Pharma America, INC. | $85.75 | 2023 | Gemtesa |
| 180 Medical, INC. | $72.14 | 2020-2023 | Gentlecath |
| Eisai INC. | $71.86 | 2020-2021 | |
| Endo USA, INC. | $69.72 | 2024-2025 | Xiaflex, Aveed, Edex |
| Endo Pharmaceuticals INC. | $65.25 | 2023-2024 | Xiaflex, Edex, Aveed |
| Merck Sharp & Dohme LLC | $48.18 | 2020-2023 | Keytruda, Lynparza |
| Shire North American Group INC | $47.54 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.53 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $36.64 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $35.95 | 2020 | |
| Telix Pharmaceuticals | $31.04 | 2024 | Illuccix |
| Bayer Healthcare Pharmaceuticals INC. | $24.89 | 2023 | |
| Abbvie INC. | $19.92 | 2022 | |
| Sunovion Pharmaceuticals INC. | $18.74 | 2020 | |
| Allergan, INC. | $18.66 | 2019 | |
| Antares Pharma, INC. | $18.45 | 2024 | Xyosted |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.43 | 2020 | |
| Medtronic, INC. | $15.63 | 2025 | Endurant Iis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bert Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.